Mia's Feed
Medical News & Research

Analysis Reveals Lack of Transparency and Penalties for Serious Errors in Rehab Hospitals

Analysis Reveals Lack of Transparency and Penalties for Serious Errors in Rehab Hospitals

Share this article

A recent analysis uncovers serious safety issues in rehab hospitals, including patient deaths and medication errors, with limited penalties and transparency from federal agencies. Learn about the risks and oversight gaps in this profitable industry.

3 min read

Rehabilitation hospitals, integral to helping patients recover from major surgeries and injuries, have become a highly profitable sector within healthcare. However, federal reports and inspections highlight troubling issues, including rare but severe incidents of patient harm and subpar safety performance, particularly at facilities operated by companies like Encompass Health Corp. Despite these serious problems, such as patient deaths and medication errors, federal agencies have not consistently disclosed these incidents to the public or applied significant penalties comparable to those in nursing homes.

For example, in 2021, a notable case involved Elizabeth VanBibber, a 73-year-old patient fatally poisoned by carbon monoxide at Encompass's Huntington, West Virginia hospital during ongoing construction. The hospital had been warned about safety precautions, yet a construction-related gas leak led to her death. The case is still pending in court, with allegations of neglect and failure to ensure a safe environment. Several other grave incidents include a patient found dead from an undetected health complication, and instances of medication errors resulting in fatalities. These incidents reveal systemic safety lapses, yet federal oversight often limits actions to routine inspections, and no fines were levied for many violations.

While some Encompass hospitals have been flagged for immediate jeopardy violations—conditions that pose imminent safety risks—these have rarely resulted in significant punitive measures, as Medicare law does not permit fines for safety violations in rehab hospitals, unlike in nursing homes. The sole exception involved a California hospital fined for a medication error after a patient’s death.

Encompass, which owns 168 hospitals and is a major player in the industry, has expanded rapidly, often entering new markets by partnering with local nonprofits and persuading them to shutter rehab units in exchange for shares. The company's financial health is robust, with declining but still significant profits, and it has a controversial history, including past involvement in massive accounting fraud under its former incarnation as HealthSouth.

In addition to safety concerns, medication errors remain prevalent. Inspection reports documented cases where patients received incorrect or improper medications, sometimes with fatal consequences. Despite these risks, federal oversight is limited, and measures like star ratings for rehab facilities—common for nursing homes—are not yet implemented, leaving consumers without transparent safety and quality information.

Overall, the current system fails to sufficiently penalize or disclose grave errors in rehab hospitals, putting patients at risk without adequate oversight or accountability. Industry experts and advocates argue that stronger enforcement and public reporting are critical steps needed to improve safety and transparency in this crucial healthcare sector.

source: https://medicalxpress.com/news/2025-07-grave-errors-rehab-hospitals-unpenalized.html

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Scientists Caution Against Relying on AI for Stroke Care

Research highlights the limitations of current AI chatbots in providing safe and accurate guidance for stroke care, stressing the need for human oversight in medical applications.

FDA Approves Expanded Use of Vonvendi for All Types of Von Willebrand Disease

The FDA has expanded approval for Vonvendi, a recombinant von Willebrand factor, to include routine prevention and treatment of bleeding in all types of von Willebrand disease, including pediatric use, enhancing care options for this rare bleeding disorder.

FDA Study Finds High Doses of Consumer CBD May Increase Liver Enzymes

A new FDA study indicates that high doses of consumer CBD, around 400 mg daily, may elevate liver enzymes in healthy adults, underscoring the need for careful monitoring and further safety research.

Innovative Biocompatible Sealant Offers Superior Healing for Soft Organ Injuries

A new injectable hydrogel sealant developed by researchers promises rapid healing and strong adhesion for soft, elastic tissues such as lungs and blood vessels, improving trauma treatment outcomes.